Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox®) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum

ObjectiveTo evaluate the effectiveness and toxicity of distearoylphosphatidylcholine pegylated liposomal doxorubicin (DPLD) combined with carboplatin for the treatment of platinum-sensitive, paclitaxel-pretreated, recurrent, epithelial ovarian cancer.MethodsA phase II study of carboplatin/DPLD treatment for platinum-sensitive, paclitaxel-pretreated, recurrent, epithelial ovarian cancer was initiated in July 2002. As of March 2008, a total of 32 patients were enrolled.ResultsOf the 32 patients, one achieved a complete response; 19 (59%) achieved a partial response. The overall objective response rate was 62% (95% confidence interval [CI], 45%–80%). The median progression-free survival and overall survival for all 32 patients was 9.1 months (95% CI, 6.4–10.4 months) and 27.9 months (95% CI, 13.9–38.6 months), respectively. Toxicity was tolerable. The most common grade 3 or 4 toxicities were anemia (n = 3) and nausea/vomiting (n = 3). Grade 3/4 leukopenia (n = 2), grade 3/4 thrombocytopenia (n = 2) and grade 4 hepatitis (n = 1) occurred in five patients.ConclusionCarboplatin/DPLD appears to be an effective regimen with low toxicity for treatment of patients with platinum-sensitive, paclitaxel-pretreated, recurrent, epithelial ovarian cancer.